Non-coronary atherosclerosis by Gallino, Augusto et al.
REVIEW
Non-coronary atherosclerosis
Augusto Gallino1,2†‡*, Victor Aboyans3,4,5†, Curt Diehm6, Francesco Cosentino7,
Hans Stricker1,2, Erling Falk8, Olaf Schouten9, John Lekakis10, Beatrice Amann-Vesti11,
Francesco Siclari12, Pavel Poredos13, Salvatore Novo14, Marianne Brodmann15,
Karl-Ludwig Schulte16, Charalambos Vlachopoulos17, Raffaele De Caterina18,
Peter Libby19, and Iris Baumgartner20, On behalf of the European Society of Cardiology
Working Group on Peripheral Circulation
1Division of Vascular Medicine, Ospedale San Giovanni, 6500 Bellinzona, Switzerland; 2University of Zu¨rich, Zu¨rich, Switzerland; 3Department of Cardiology, Dupuytren University
Hospital, Limoges, France; 4INSERM 1094, Limoges, France; 5Faculte´ de Me´decine, Inserm U1064 Neuroe´pide´miologie Tropicale, F-87025, Limoges, France; 6 Department of Internal
Medicine, SRH Klinikum Karlsbad, 76307 Karlsbad, Germany; 7Division of Cardiology, Osp. S. Andrea-University Sapienza, 00189 Rome, Italy; 8Department of Cardiology, Aarhus
University Hospital, 8200 Aarhus, Denmark; 9Erasmus University Hospital, 2593GT Den Haag, Netherlands; 10Cardiology Department, Attikon University Hospital, Athens, Greece;
11Angiology Department, University Hospital, 8091 Zurich, Switzerland; 12Cardiosurgery Department, Cardiocentro CCT, 6900 Lugano, Switzerland; 13Department of Vascular
Medicine, University Medical Centre Ljubljana, 1525 Ljubljana, Slovenia; 14Department of Cardiology, University Hospital Palermo, 90144 Palermo, Italy; 15Department of Angiology,
University Hospital Graz, 8036 Graz, Austria; 16Vascular Center Berlin, Ev. Hospital KEH, Academic Teaching Hospital Charite´, 10365 Berlin, Germany; 17Cardiology Department, Athens
University Medical School, Athens, Greece; 18Institute of Cardiology Department, ‘G. d’Annunzio’ University-Chieti, Ospedale SS.Annunziata, 66013 Chieti, Italy; 19Cardiovascular
Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA; and 20Angiology Dep., University Hospital Berne (Inselspital), 3000 Berne, Switzerland
Received 26 June 2013; revised 29 January 2014; accepted 2 February 2014; online publish-ahead-of-print 3 March 2014
During the last decades, the clinical and research interest in atherosclerosis has been mostly focused on coronary arteries. After the publications
of the European Society Guidelines and AHA/ACC Guidelines on Peripheral artery diseases, and of the Registry REduction in Atherothrombosis
forContinuedHealthRegistry, therehasbeenan increased interest in atherosclerosisof the lowerextremityarteries and itspresence inmultifocal
disease. However, awareness in the general population and the medical community of non-coronary artery diseases, and of its major prognostic
implications remain relatively low. The aim of this general review stemming out of an ESC Working Group on Peripheral Circulation meeting in
2011 is to enhance awareness of this complex disease highlighting the importance of the involvement of atherosclerosis at different levels with
respect to clinical presentation, diagnosis, and co-existence of the disease in the distinct arterial territories. We also emphasize the need of an
interdisciplinary approach to face the broad and complex spectrum of multifocal disease, and try to propose a series of tentative recommenda-
tions and measures to be implemented in non-coronary atherosclerosis.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Peripheral artery circulation † Atherosclerosis
Introduction
There is an increased interest among the medical community fornon-
coronary atherosclerosis. The most important recent initiatives in
this field have been the new ESC Guidelines on the diagnosis and
treatment of peripheral artery diseases,1 the ACC/AHA Practice
Guidelines in management of patients with peripheral artery
disease,2,3 the Trans-Atlantic Inter-Society Consensus for the Man-
agement of Peripheral Arterial Disease (TASC I and II),4,5 which all
have established important educational, clinical, and research goals
for the near future.
The pivotal results of several epidemiological studies—among
others—the Basel, and the Ankle-Brachial Index Collaboration
study6,7 have also highlighted this interest, with the former demon-
strating as early as the 60s the poor prognosis of patients with
lower extremity artery disease (LEAD). More recently, the GetABI
and the Registry Reduction in Atherothrombosis for Continued
Health Registry (REACH)8,9 have highlighted the role of atheroscler-
osis as a systemic disease with manifestations in multiple vascular
beds, and indicated that these patients have a poorer prognosis
than patients with just one territory affected9 (Figure 1). The ability
by a simple diagnostic tool as the measurement of the ankle-brachial
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index (ABI), a surrogate and objective equivalent of the presence of
LEAD, to anticipate overall cardiovascular prognosis and apply pre-
vention strategies has increased the attention for this field.8,10–12
(Figure 2) Cardiologists in fact—as elegantly demonstrated by the
initial career as specialist in vascular medicine of Andreas Gruentzig
and his invention of angioplasty13—have always been aware of the
need of a multifocal diagnostic and therapeutic approach because
atherosclerosis has a common pathogenesis, and simultaneously
affects multiple circulatory regions.
This review has been conceived following an ESC Working Group
on Peripheral Circulation meeting held in Zu¨rich in 2011 convening
20 cardiovascular specialists in peripheral circulation and athero-
sclerosis together with leading European and American cardiologists
who considered appropriate, 3 years after publication of the ESC
guidelines, to reinforce this relevant problem since its knowledge in
cardiology community tends to be low. It focuses the attention on
atherosclerosis affecting the different non-coronary arterial territor-
ies, from the upper limbs arteries, the extra-cranial carotid through
the thoracic and abdominal aorta, the mesenteric, renal, and lower
limbs arteries, and emphasizes the growing and often unrecognized
burden of vascular disease. Special attention is given to the issue of
multifocal atherosclerosis, and the need for an interdisciplinary man-
agement. Given the vast extension of the topic, all facets of vascular
diseases cannot be covered in detail, and some aspects go beyond the
scope of the paper, i.e. therapeutic strategies, and will not be covered
in this review. Finally, practical suggestions for clinicians and policy
makers to increase awareness on this important item, also highlight-
ing some areas of uncertainties in this field, are proposed.
Upper extremity arteries
In contrast to many other territories, overt atherosclerosis of the
upper limb arteries, including the case for the thoracic artery is rela-
tively rare since 3–4% of the general public have a subclavian stenosis
and 15–20% of patients with LEAD have it.14 Conversely, it is intri-
guing to see how the upper extremity arteries (i.e. the brachial arter-
ies) are the more convenient territory to assess non-invasively the
endothelial dysfunction, one powerful early indicator of subclinical
atherosclerosis. Endothelial dysfunction assessed by ultrasound
measurement of the brachial artery flow-mediated dilation (FMD)
after reactive hyperaemia or cold pressor test may provide prognos-
tic information even in the absence of overt atherosclerosis, antici-
pating progression of the atherosclerotic lesions in patients with
coronary artery disease, and in patients with LEAD.15 Measurement
of endothelial function has been of paramount importance for the
understanding of pathophysiology of early and late manifestations
of atherosclerosis and its complications, for determining the import-
ance of traditional and emerging risk factors of atherosclerosis as well
Figure 1 One-year cardiovascular event rates as a function of
number of symptomatic disease locations. All P-values , 0.001.
CV, cardiovascular; MI, myocardial infarction. Patients with at
least three factors but no symptoms are counted as 0, even in the
presence of asymptomatic carotid plaque or reduced ankle brachial
index. Error bars represent 95% confidence intervals (adapted from
Steg et al.9 with permission by the publisher).
Figure2 Hazard ratios for total mortality in men and women by ankle-brachial index at baseline for all studies combined in the ABI Collaboration
(adapted from Aboyans et al.12 with permission by the author and the publisher).
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as for the comprehension of the mechanisms of action of several drug
families and lifestyle changes crucial for the prevention as well as
treatment of atherosclerosis, i.e. ACE inhibitors, and statins. A low
brachial artery FMD is an independent predictor of cardiovascular
risk.16 Overall, the clinical relevance of upper limb atherosclerosis,
and the use of FMD in the clinical arena remain relatively low, since
the latter—in spite of its valid proof of concept—has not reached suf-
ficient clinical utility.
Carotid arteries
The relevance of extra-cranial cerebral artery atherosclerosis is
two-fold. From a clinical standpoint, carotid atherosclerosis is re-
sponsible for 25% of strokes with major impact on disability of
the growing older population.17– 19 From a clinical research stand-
point, carotid atherosclerosis represents an extraordinary window
to study in vivo early and late manifestations of atherosclerosis.20,21
The earliest visible manifestation of carotid artery disease is the thick-
ening of the intima-media which is detectable with high-resolution
B-mode carotid ultrasonography (Duplex US),22 a marker of early
subclinical atherosclerosis which correlates with incident vascular
outcomes, i.e. stroke and coronary heart disease. A recent
meta-analysis by Lorenz et al. showed the strong predictive value
of carotid intima-media thickness for the occurrence of cardiovascu-
lar events.20 The morphological presentation of atherosclerotic
plaques at the level of carotid arteries with a lipid core and fibrous
cap is similar but not exactly the same than those found in other vas-
cular areas.23,24 Carotid atherosclerotic plaques are associated with
embolization of superimposed thrombotic material,2,4,24,25 a phe-
nomenon which is clinically relatively less relevant at the level of cor-
onary arteries or lower limbs arteries.1– 5 It has been assumed that
the riskof embolization orcomplicationsof carotid plaques increases
in parallel with the degree of obstruction although the complexity of
the plaque probably plays an even more important role.25 The annual
risk of stroke in patients with asymptomatic carotid stenosis
(between 50 and 99%) is 1.0–3.3% with the higher incidence in
those with the more severe stenosis and more rapid progression of
stenosis.2,4,25 Patients with symptomatic carotid artery stenosis
with previous stroke have an annual recurrent stroke risk of
between 10 and 43%.23,25 However, it should be emphasized that
most of these studies22,23 have been performed before the wide-
spread use of statins, which may induce stabilization or reduction in
carotid atherosclerotic plaque.2,26 Duplex US is the standard tool
in clinical practice for detection and estimates the degree of severity
of carotid atherosclerosis.27 Duplex US allows to estimate not only
the degree of stenosis but also the extension and complexity of the
plaque lesion; echogenicity detected by Duplex US ultrasound has
been proposed to identify lesions at higher risk of spontaneous com-
plication or following invasive treatment (i.e. carotid surgeryor stent-
ing).28 Contrast-enhanced Duplex US is another emerging
application of ultrasound imaging which may allow the identification
of intraplaque neovascularisation, a further potential predictor of
plaque vulnerability.29
Spiral CT, and particularly MRI plaque imaging may add important
information on plaques composition and vulnerability-detecting
plaque rupture, intraplaque haemorrhage, and the presence of
thrombus.21,30–32 Recently, PET/CT-scan and hybrid techniques
prototypes using PET/CT and MRI seem to be promising research
tools for identifying inflammatory component of atherosclerotic
plaques.32 However, so far the use of these techniques is proposed
only to investigational purpose and are not used clinically.
Thoracic and abdominal aorta
The pathology of the aorta has several peculiar aspects. Atheroscler-
otic involvement of the thoracic ascending aorta and of the aortic
arch has been recognized as a significant source of ‘spontaneous’
cerebral and peripheral thromboembolism and may represent a dan-
gerous source of atherothrombotic embolism during diagnostic and
invasive procedures (PCI, on-pump cardiac surgery).33 Transesopha-
geal echocardiography is one of the most powerful tools to detect
mobile and complex plaques at the level of the aortic arch and of
the descending aorta.33,34
A clinically distinct feature is the athero-embolic syndrome asso-
ciated with severe aortic atherosclerosis and embolization from
ulcerated plaques. Hallmark of this syndrome is renal insufficiency,
skin lesions, blue toe(s), caused by micro-emboli associated with
transient eosinophilia.35 It can occur spontaneously, but frequently
results from arterial manipulation, such as catheter intervention
and aortotomy.36 Prognosis is poor with 1-year mortality rates
between 60 and 81%, although this high mortality may reflect selec-
tion bias due to the fact that these figuresderive from autopsystudies.
Over 70% of patients with athero-embolic syndrome present renal
function impairment and over 40% of these patients end-up with
severe renal failure needing dialysis.35,36
Aortic aneurysms have been traditionally considered a special
form of atherosclerosis, because this disorder is almost always asso-
ciated with severe atherosclerotic damage of the aortic wall, and
because it shares many of the same risk factors as obstructive athero-
sclerosis. However, this conventional view has been challenged in
recent years: basic and clinical research studies indicate that aneur-
ysms arise through pathogenic mechanisms that are distinct from
those responsible for athero-occlusive disease.37,38
Renal arteries
Haemodynamically significant renal artery stenosis (RAS) is asso-
ciated with hypo-perfusion of the renal parenchyma which induces
a series of (patho)-physiological responses, including upregulation
of the renin–angiotensin–aldosterone system followed by fluid re-
tention, reduced natriuresis, and vasoconstriction which may
end-up with perpetuation of arterial hypertension , renal fibrosis,
and renal function impairment.39,40 The recent refinement and
increasing use of diagnostic procedures such as Duplex US ultra-
sound,41 angio-CT, andmagnetic resonance42 in the older population
with diffuse atherosclerosis undergoing invasive diagnostic proce-
dures (i.e. coronary angiography) have changed the spectrum of clin-
ical presentation of RAS. Cardiologists face relatively frequently the
management of patients with multi-morbid poly-vascular patients
with uni- (or bilateral) atherosclerotic obstructive disease of the
renal arteries. These patients may present with renal with resistant
arterial hypertension, renal function deterioration, ‘flash’ pulmonary
oedema, and unstable angina.43
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Mesenteric artery
The prevalence of acute and chronic mesenteric ischaemia is low, but
its clinical relevance is high since ischaemia may be often fatal particu-
larly in cases of acute presentation.1 –5 Mesenteric ischaemia may be
caused by atherosclerosis, arterial emboli, or thrombosis as well as
several other rare pathologies affecting the mesenteric arteries
(fibro muscular dysplasia, arterial infection, aneurysms, or dissec-
tions). Acute mesenteric ischaemia is often a result of cardio-embolic
events or due to embolization following endovascular procedures.
Other causes are arterial thrombosis based on a pre-existent stenot-
ic lesion, acute aortic dissection, or hypercoagulability states. Patients
with acute mesenteric ischaemia often present with abdominal pain
out of proportion to physical findings associated with leukocytosis
and lactic acidosis, and have frequently a history of cardiovascular
disease or a recent history of cardiovascular intervention.2,44
Computer tomography is the diagnostic tool to identify thrombosis
of the proximal intestinal arteries and its consequences (intestinal
wall thickening, distension, abdominal fluid, or perforation). Chronic
intestinal ischaemia affects predominantly women. Patients often
present with postprandial abdominal pain frequently associated
with weight loss, although the absence of the typical postprandial dis-
comfort is not infrequent, making this diagnosis very challenging.44
While Duplex US is often the first row imaging method, CT (and/
or MRI) are the most adequate investigations to detect the affected
vessels causing ischaemia and its consequences. The sensitivity and
specificity for detection of mesenteric ischaemiawith newermultide-
tector CT and magnetic are for both .90%.45,46
Lower extremity arteries
Oneof the most recently re-discovered aspects of non-coronaryath-
erosclerosis is the major prognostic impact of the presence of
a symptomatic or asymptomatic atherosclerotic involvement of
the peripheral arteries of the lower limbs (LEAD).1– 5,8,47,48 The
prevalence of LEAD is high especially, in subjects over the age of 65
(Figure 3).The life expectancy of a patient with severe claudication
is ,80% at 5 years follow-up, and an additional 20% of patients
suffer of non-fatal cardiovascular events.5,48 Patients with more
moderate symptoms or asymptomatic LEAD are also at significant
higher risk to die because of cardio- or cerebrovascular complica-
tions.1–5,8,47,48 (Figure 1) In spite of this poor survival prognosis,
patients with LEAD have received until recently scant public attention,
half of claudicants being not recognized as such.1–5,9,11,49,50 Once diag-
nosed, patients with LEAD have significantly less chance of receiving
appropriate risk factor modification, statins, and antithrombotic treat-
ment than patients with coronary or cerebrovascular disease.9,11,11,50
Awareness of this condition should be promoted by the use of
simple diagnostic tools such as measurement of the ABI, in order to
detect a larger population of high-risk patients who should receive ap-
propriate cardiovascular treatment.1–5,9,11 The poor general progno-
sis of these patients contrasts with the relatively benign course of the
local disease, only 25% of patients experience symptomatic deterior-
ation, and 2–6% eventually lose the involved leg within 5 years.1–5
Critical limb ischaemia (CLI) deserves a special place in the spec-
trum of LEAD since it is a hallmarkof dismal prognosis in terms of sur-
vival (up to 45% mortality within 1 year) and limb loss.51 It is clinically
defined by the presence of rest pain or gangrene associated with
chronic ischaemia, and is usually associated with an ankle pressure
≤50 mmHg. It may develop slowly or occur with acute onset of
symptoms in patients following distal athero-embolisation or in
patients with multisegmental atherothrombosis.1– 5 It should be
clearly differentiated from acute limb ischaemia, although the latter
is also associated with risk of amputation: it follows acute arterial em-
bolism and is accompanied by acute onset of symptoms with an
obvious embolic source (atrial fibrillation, left ventricular aneurysm,
atheromatous plaque in the aorta, or mural thrombus of arterial an-
eurysm), absence of previous claudication, and the presence of
normal arterial pulses and Doppler systolic blood pressures in the
contralateral extremity.1– 5,51
From the clinical research standpoint, atherosclerosis of the lower
extremities still remains an important model to study ‘in vivo’ patho-
physiology of atherosclerosis such as the studyof arterial remodelling
52,53 and new treatment strategies as it was the case for angioplasty
which was first introduced by A. Gruentzig to treat non-coronary
atherosclerotic obstructions at the level of the lower limb arteries
before being applied to the coronary arteries.13
A further example of how peripheral vascular medicine may be
relevant to explore new cardiovascular revascularization strategies
is angiogenesis. Intensive research in this field undertaken by
J. Isner, another cardiologist interested in peripheral artery disease,
allowed new insight into the complex issue of CLI, microcirculation
and potential treatment modalities which have been relevant also
for other territories (i.e. myocardium).54,55 Through the emphasis
on the importance of a global view of multisite atherosclerosis, and
a close contact among internationalists in distinct arterial fields,
there is a steady increasing mutual influence between coronary and
non-coronary vascular specialists.
Multifocal atherosclerosis
The REACHregistryhas clearly confirmed that the presence ofmulti-
focal atherosclerosis has a major clinical and prognostic impact
Figure 3 Estimated prevalence of peripheral arterial disease in
the European Union. Estimation obtained through http://europa.
eu.int/en/comm/eurostat/eurostat.html and estimation form
GetABI study* (adapted from Diehm and Baumgartner38)**.
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(Figures 1 and 2).1–5,9 The co-coexistence of coronary artery disease
plays obviously a major prognostic role in terms of mortality.1,6
Apart from the deemed spontaneous prognosis this may be important
in those patients scheduled and undergoing vascular revascularization
procedures, although the conclusions of a recent multicentre trial in
patients scheduled for major vascular interventions did not show a sig-
nificant benefit in patients undergoing preoperative coronary evalu-
ation and revascularization (Table 1 and 2).56
The cause of the different prevalence of atherosclerosis at the
level of distinct territories is complex. Loco-regional hemodynamic
and rheological factors as a turbulent flow at bifurcations or side
branches are also important mechanisms predisposing and favouring
the progression of atherosclerotic lesions.2,4 The distribution,
predominance, and co-existence of atherosclerosis at different loca-
lizations of the arterial tree remain however frequently elusive, al-
though some clues of distribution emerge from epidemiological
series. Genetic, traditional, and/or emerging risk factors, inflamma-
tory markers, environmental and socio-economic factors all may
play an important role.1– 5,57– 59 The different prevalence of classic
risk factors in the various territories are important for both predom-
inance and prognosis: smoking is three times more likely to cause
LEAD than coronary artery disease.60 Conversely, the association
of hypertension with LEAD is lower than the association of hyperten-
sion with coronary artery disease or cerebrovascular disease.61
Indeed, patients with carotid atherosclerosis present a stronger rela-
tionship with arterial hypertension (and benefit more of antihyper-
tensive treatment) than patients with coronary atherosclerosis.62
Multifocal atherosclerosis
in patients with lower extremity
artery disease as primary
manifestation of disease
Patients with LEAD have a poor prognosis as this disease is associated
with two- to six-fold risk of coronary and cerebrovascular disease,
when compared with the normal population.1 –5,63–71 In fact, the
presenceofLEAD in itself constitutes averypotent risk factorequiva-
lent. The severity of LEAD goes hand in hand with an increased
cardio- and cerebrovascular morbidity and mortality. Patients with
more severe claudication present a higher prevalence of CAD and
CVD than those with mild symptoms, and patients presenting with
CLI, i.e. with rest pain or gangrene, will have the highest associated
cardiovascular morbidity and mortality (up to 90% incidence of
CAD and 1-year mortality ranging from 25 to 50%).1– 5,51 Cardiolo-
gists should better be aware of these figures while treating patients
with LEAD not only because of the deemed spontaneous prognosis
but also when estimating the risk of a surgical intervention. The pres-
ence of LEAD stratify the patient into a higher risk group. One-third
of patients with LEAD present coronaryartery disease on the basis of
historyandelectrocardiogramtwo-thirdson thebasisof an abnormal
stress test and up to 70% present at least single vessel disease at cor-
onary angiography. Whether a silent concomitant CAD should be
confirmed and treated by an invasive procedure depends at the
end upon the cardiac indication to coronary angiography and revas-
cularisation.56
The risk of stroke in male patients with LEAD has been reported
four to five times higher than in patients without LEAD.71 Approxi-
mately 20% of patients with LEAD have a significant carotid stenosis
detected at Duplex US ultrasound.1– 5,65,66 The severity of LEAD
seems to correlate with the severity of carotid artery stenosis.67
The presence of carotid bruits in LEAD patients should foster the
search of carotid internal stenosis, i.e. by Duplex US: subsequent
diagnostic and therapeutic strategies are driven again by the clinical
presentation and the degree of the concomitant carotid stenosis.
Multifocal involvement in patients
presenting with carotid arteries
atherosclerosis
Patients with significant carotid artery disease (i.e. stenosis . 70–
80%) are more prone to die following acute coronary syndrome
than cerebrovascular events, pointing to the high prevalence of con-
comitant coronary artery disease.72 Thus, patients with carotid
artery disease should undergo aggressive medical treatment of
their risk factors in analogy to patients with ‘lone’ coronary artery
disease.
Patients with symptomatic carotid artery atherosclerosis have per
se a 30% and 20% co-prevalence of CAD and LEAD respectively.1–3,58
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Table 1 Non-coronary atherosclerosis: co-prevalence in other territories
Affected
territory
Carotid arteries Aorta Renal arteries
Clinical
presentation
ICA < 60%
asymptomatic
ICA > 60%
asymptomatic
ICA > 70%
symptomatic
Athero-embolism Thoracic
aneurysm
Abdominal
aneurysm
Hypertension
or renal failure
Associated atherosclerosis
CAD up to 25% up to 35% .50% up to 40% .50% up to 90%
CVD .50% up to 20% .50% up to 60%
PAD up to 10% up to 20% .50% up to 30% .50% up to 60%
CAD, coronary artery disease; CVD, cerebro-vascular disease; ICA, internal carotid artery stenosis; PAD, lower limb artery disease.
Co-prevalence estimated according: Circulation 2006;113:e463–e465; Dormandy and Rutherford4; Tendera et al.1; J Vasc Surg 1994;19:668–74; Circulation 2006.
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Recent studies indicate that patients with cerebrovascular athero-
sclerosis also have simultaneous subclinical LEAD as detected by
Duplex US and the ABI.73,74 Whether and how a patient with signifi-
cant carotid artery disease should be screened for the concomitancy
of CAD remains a question of debate even in case of a planned inva-
sive surgical carotid revascularization procedure.1 – 3 The bottom line
remains that, in the presence of cerebrovascular atherosclerosis, the
concomitant involvement of other territories is not infrequent, and in
case of clinical suspicion should be actively searched by non-invasive
methods.
Patients presenting with aortic
aneurysms as primary
manifestation of disease
It is well known that patients with aortic aneurysms present with
higher prevalence of smoking, hypertension which are associated
with diffuse atherosclerosis with high cardiac and vascular co-
morbidities, i.e. coronary artery disease, heart failure, and carotid
artery, and/or LEAD. The presence of concomitant coronary athero-
sclerosis in patients undergoing abdominal (or thoracic) aneurysm
repair has been extensively studied and its prevalence depends on
the screening method (up to 50% according to the method of detec-
tion).2,3,75 The high concomitant cardiovascular co-morbidity is a
matter of major concern especially in patients needing open aortic
repair who have symptomatic coronary artery disease or decompen-
sated heart failure.1 –5,76 Conversely, in patients with stable coronary
artery disease, the risk of cardiovascular events during aortic repair
seems nowadays relatively low, obviating the need of preventive cor-
onary revascularization.56
Patients presenting with renal
atherosclerosis
Patients with unilateral and—most importantly—with bilateral renal
artery atherosclerotic obstructions have a dismal prognosis because
they probably represent a marker of the burden of global athero-
sclerosis.40 Renal function impairment in these cases seems to per-
petuate and accelerate the process of systemic atherosclerosis
which is associated in patients with chronic kidney disease with a car-
diovascular mortality of 30–50%.1,40,43,77
Comprehensive approach
Given the broad spectrum of non-coronary atherosclerosis, there is
a need for a comprehensive approach. When facing a patient with
non-coronary artery disease, one has to keep in mind the frequent
systemic feature of the disease, i.e. the potential involvement of
other territories, i.e. coronary or cerebrovascular arteries making
the cardiologist a natural player in the management of these patholo-
gies. This may especially be relevant not only for prognostic purposes
but, most importantly, in cases where revascularisation is needed in
order to plan and prioritize which territory should be firstly
treated (concomitant or staged procedures). As recently under-
scored by the 2011 ESC guidelines on Peripheral Artery Diseases
and by the NHLBI, a multidisciplinary team including specialists in car-
diovascular medicine, vascular surgery, radiology and even some-
times other fields according to the organs involved should take
care of these patients. Recently, an EU division in vascular medicine
has been officially recognized by the UE regulatory agency
(UEMS)* in Europe, and a National Institute of Health (NIH) fellow-
ship in clinical vascular medicine has been advocated in the USA**.
This speciality/fellowship includes a 2- to 3-year training period
with intensive teaching in basic, clinical, pathophysiology, non-
invasive and invasive diagnostic, prevention and therapeutic strat-
egies in vascular medicine.
Multidisciplinary boards, pending upon the local situation, may be
moreefficientwhen theseorganization models are integrated prefer-
ably into a broad cardiovascular concept, i.e. within cardiovascular
centres. Major efforts in this direction should be pursued in order
to better achieve a global management of patients with non-coronary
and coronary atherosclerosis.
*UEMS—European Union of Medical Specialists http://www.uems.
net/EU—Division of Angiology
**NHLBI Vascular Medicine Training Programme Working Group
Executive Summary http://www.nhlbi.nih.gov/Meetings/workshops/
vascular-med.htm
Economical impact of
non-coronary atherosclerosis
The results of REACH Registry—a large, international, prospective
study of stable outpatient population with either established symp-
tomatic atherothrombosis (CAD, cerebrovascular disease, or
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Table 2 Lower limb artery disease: co-prevalence in other territories
Affected territory Lower limb arteries
Clinical presentation Asymptomatic ABI <0.9 Intermittent claudication Acute limb ischaemia Chronic CLI Aneurysm
Associated atherosclerosis
CAD Up to 50% AF frequent Up to 90% Up to 50%
CVD Up to 20% .50% Up to 60% Up to 20%
ABI, ankle-brachial index; AF, atrial fibrillation, CAD, coronary artery disease; CVD, cerebrovascular disease.
Co-prevalence estimated according: J Vasc Surg 1994;19:668–74; Tendera et al.1; Circulation 2006;113:e463–e465; Dormandy and Rutherford4.
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LEAD)—have clearly indicated that symptomatic LEAD is associated
with the greatest costs when compared with coronary artery disease
and cerebrovascular disease.78,79 (Figure 4) In this registry, the
authors compared the rates of associated costs in the USA with
LEAD across patient subgroups as well as the incidence of vascular-
related hospitalizations. Patients with symptomatic LEAD at
enrolment were defined on the basis of presence of intermittent
claudication with an ABI, 0.90 or a history of previous lower
limb revascularization (or amputation). Asymptomatic LEAD was
defined when ABI < 0.90 in the absence of symptoms. A total of
2396 (9.3%) had symptomatic and 213 (0.8%) had asymptomatic
LEAD at baseline were considered for the cost analysis. Based on
the results of the American REACH cohort and of the 2004 US
census data, the total annual costs associated with vascular hospita-
lizations in patients with LEAD would excess $21 billion. Similar
results and cost extrapolations have been observed in several Euro-
pean cohorts of the REACH Registry where 2-year hospitalization
costs were highest for patients with LEAD.80 These data emphasize
the need for an early and aggressive identification, prevention, and
treatment of LEAD which is clearly underdiagnosed and under-
treated. Several further studies have underlinedhow LEAD is respon-
sible of a major proportion of the burden on healthcare systems
beyond from indirect costs, as those related to lost productivity.81
All these costs could potentially be reduced, i.e. through long-term
prevention, when the disease would be recognized at an earlier
stage, although such long-term prevention is expensive on its
own.82 Therefore, there is a need for further prospective studies
on cost efficacy of long-term preventions strategies in the setting of
non-coronary atherosclerosis, and in patients with LEAD which
may allow to draw more solid cost-efficacy conclusions. The same
holds also true in the field of cost–benefit analysis of revasculariza-
tion procedures in LEAD where there is also a need of prospective
studies including long-term standardized evaluation of patient-
centric results, and re-intervention outcomes as reported in a
recent a systematic review of the Mayo clinic on economic evaluation
of LEAD revascularization procedures.83
Areas of uncertainty
Compared with CAD where a huge amount of prospective data
based on RCTs has been generated during the last three decades
on diagnostic-, preventive-, and therapeutic strategies, clinical re-
search in non-coronary and multisite atherosclerosis—as reported
in Table 3 and 4—has suffered of a relatively limited interest, and
large RCTs are generally lacking. This may be related to the frequent
involvement of multiple arterial districts preventing to focus in detail
on each arterial area. Thus, several data on management of LEAD and
on carotid artery disease are frequently extrapolated from results
derived from CAD. Although the relevance of traditional risk
factors has been evaluated in patients with LEAD, the role of emer-
gent risk factors and of drug prevention has been limited studied in
large prospective studies. We also have poor data on the causes of
different behaviour in progression of atherosclerosis among the dis-
tinct arterial sites.
Data regarding multisite atherosclerosis are lacking: the usefulness
of carotid revascularization in asymptomatic patients with .80%
Figure 4 Data from the One-Year Costs in Patients With a
History of or at Risk for Atherothrombosis in the United States
Costs across patient subgroups defined according to specific arter-
ial bed(s) affected and the number of affected arterial beds. Total
costs per patient (mean, with 95% confidence interval) adjusted
for covariates by presence of multiple risk factors only and
number of diseased vascular beds (cerebrovascular, coronary,
and peripheral). Hosp, hospitalization; MRFs, multiple risk factors.
There is a consistent increase in costs with each additional diseased
arterial bed. (Adapted from Circulation Outcomes 2008;1:
38–45).79
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Key messages by the panelists
Key messages
Prevalence of LEAD in subjects .60 years is higher than actually
perceived by the medical community
Prognosis in LEAD (independent of symptoms) is poor
Multivascular atherosclerosis is frequent in the presence of LEAD
and is associated with high morbidity and mortality
Patients with LEAD and multivascular disease receive insufficient
primary and secondary prevention
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Measures to be implemented in non-coronary
atherosclerosis
Measures to be implemented in non-coronary atherosclerosis
Further increase awareness in the cardiology community and in the
public of the clinical and prognostic relevance of LEAD
Increase awareness of the importance of multivascular disease
Females with LEAD should receive more attention
The use of ABI as a diagnostic and prognostic tool should be encouraged
among GPs and specialists
RCTs and Surveys on LEAD and multisite atherosclerosis are needed
A. Gallino et al.1118
internal carotid stenosis before CABG remains uncertain. The
optimal timing (staged or synchronous), and the method for
carotid revascularization (carotid endarterectomy or stenting) in
patients undergoing CABG have not yet been clearly identified.
Conclusions
Non-coronary atherosclerosis includes a large spectrum of disease
with distinct manifestations at different vascular locations; it may
occur in isolated form or—more frequently—simultaneously at
various sites. Associated CAD is frequent especially in the case of
lower limb atherosclerosis, which is a powerful predictor of mortal-
ity, hospitalizations, and costs. Awareness of the disease and active
screening for non-coronary atherosclerosis using simple diagnostic
tools are essentials for the detection of disease. Once diagnosed
efforts should be made for a holistic management aiming at treat-
ing and preventing the whole spectrum of the disease and their
complications.2
This review by the ESC Working Group on Peripheral Circulation
and by the panellists of the 2011 Zu¨rich meeting suggest some tenta-
tive strategies (Table 3, 4, 5) in order to further improve management,
and to increase visibility of non-coronary atherosclerosis. The panel-
lists propose several tentative measures to be implemented in the
field non-coronary atherosclerosis and to increase awareness of
this disease complex (Tables 4 and 5). The use of ABI as a diagnostic
and prognostic tool should be more encouraged among GPs and spe-
cialists; females with LEAD should receive more attention; rando-
mized clinical trials, surveys, and registries on LEAD and multisite
atherosclerosis should also be encouraged. Awareness of the
disease should be increased through public campaigns at European,
national, and community levels. The medical communities should
be sensitized through the existing guidelines on peripheral arter-
ies,1– 5 and more emphasis on LEAD during graduate and postgradu-
ate teaching.
Conflict of interest: none declared.
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